ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Integration of network pharmacology and transcriptomics to reveal the ROS/NLRP3/Caspase-1/GSDMD-mediated mechanism of baicalin in alleviating contrast-induced acute kidney injury.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Fucoidan Ameliorates Contrast-Induced Acute Kidney Injury in Mice by Modulating the TLR4/NF-κB and Nrf2/GPX4 Pathways.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Research progress on risk factors and early predictors of contrast-induced nephropathy.American journal of translational research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Contrast-induced acute kidney injury (CI-AKI) is a major hospital-acquired renal dysfunction for which therapeutic options are limited. Scutellariae radix has traditional anti-inflammatory effects, and its main component baicalin shows potent anti-inflammatory/antioxidant activities. However, baicalin's in vivo efficacy and mechanisms in CI-AKI remain unclear. This study aimed to evaluate its therapeutic effect on iohexol-induced CI-AKI and elucidate the underlying mechanisms. C57BL/6 mice were assigned to control, CI-AKI model, and baicalin-pretreated (50 mg/kg and 100 mg/kg) groups. After CI-AKI induction, serum Scr and BUN, renal histopathology (H&E/PAS staining, RTI scores), oxidative stress (SOD, GSH-Px, MDA), and inflammation (IL-1β and IL-18) were assessed. Network pharmacology (NP) predicted baicalin's targets/pathways, and transcriptomic sequencing identified differentially expressed genes (DEGs) in the kidne. Inhibitor experiments validated the key pathway. Baicalin reduced Scr/BUN levels, alleviated renal tubular vacuolar degeneration, lowered RTI scores, regulated oxidative stress markers, and downregulated IL-1β and IL-18. NP identified 129 overlapping targets enriched in inflammation pathways; transcriptomics found 308 key DEGs. Integrated analysis highlighted the ROS/NLRP3/Caspase-1/GSDMD pathway, with baicalin's downregulation of the NLRP3/Caspase-1/GSDMD confirmed by inhibitors. Baicalin alleviates iohexol-induced CI-AKI by inhibiting the ROS/NLRP3/Caspase-1/GSDMD pathway, providing a basis for clinical application.
Indexed as
Identifiers
41384955What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.